Epizyme, Inc. (EPZM - Free Report) is scheduled to report second-quarter 2017 results on Aug 4, before the opening bell.
Last quarter, the company came up with a positive earnings surprise of 11.11%. In fact, its track record has been strong, with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive surprise of 11.09%.
Notably, Epizyme’s share price has declined 7.4% year to date against the Zacks classified industry’s gain of 9.8%.
Let’s see how things are shaping up for this quarter.
Factors Influencing This Quarter
Epizyme is a development-stage company with no approved products in its portfolio. Its top line comprise revenues earned through collaborations. Hence, investor focus is expected to remain on the company’s pipeline updates.
Currently, the company’s lead candidate, tazemetostat (an EZH2 inhibitor), is being evaluated for relapsed or refractory non-Hodgkin's lymphoma (NHL) and advanced solid tumors.
In fact, Epizyme is evaluating tazemetostat in a phase II study in adults with relapsed or refractory NHL, a phase II study in adults with certain genetically defined solid tumor (INI1-negative tumors, SMARCA4-negative tumors or synovial sarcomas). In Jun 2017, the company announced positive interim data from this study.
Also, it intends to meet with the FDA, in the second half of 2017 and discuss the NHL program, with the goal of defining its registration pathways in various subtypes.
Furthermore, the company is exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining it with an anti-PD 1 or PDL-1 agent. Notably, under its collaboration with Roche Holding AG (RHHBY - Free Report) , Epizyme is evaluating tazemetostat in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to determine the recommended phase II dose and advance into the expansion portion of the study.
The company’s other experimental candidate, pinometostat, an inhibitor of the DOT1L HMT is currently in a phase I study for the treatment of children with MLL gene (MLL-r).
As of Mar 31, Epizyme expects that its cash balance of $211.2 million will be used to fund its planned operations through at least the third quarter of 2018.
Our proven model does not conclusively show an earnings beat for Epizyme this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately that is not the case here, as you will see below.
Zacks ESP: Epizyme has an Earnings ESP of 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 56 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme has a Zacks Rank #2. This when combined with 0.00% ESP makes surprise prediction difficult.
Note that we caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Tesaro, Inc. (TSRO - Free Report) has an Earnings ESP of +16.40% and a Zacks Rank #3. The company is expected to release results on Aug 8. You can see the complete list of today’s Zacks #1 Rank stocks here.
Esperion Therapeutics, Inc. (ESPR - Free Report) has an Earnings ESP of +17.37% and a Zacks Rank #3. The company is scheduled to release results on Aug 3.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>